EAM Investors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-11,552
Closed -$2.54M 467
2020
Q4
$2.54M Sell
11,552
-364
-3% -$78.7K 0.42% 60
2020
Q3
$1.98M Buy
+11,916
New +$1.63M 0.47% 59
2020
Q1
Sell
-11,521
Closed -$1.49M 306
2019
Q4
$1.49M Sell
11,521
-6,963
-38% -$672K 0.33% 145
2019
Q3
$1.44M Sell
18,484
-16,675
-47% -$1.56M 0.38% 129
2019
Q2
$3.62M Sell
35,159
-4,556
-11% -$355K 0.89% 10
2019
Q1
$2.91M Buy
+39,715
New +$2.7M 0.71% 28
2018
Q4
Sell
-68,981
Closed -$3.25M 337
2018
Q3
$3.25M Sell
68,981
-30,675
-31% -$1.71M 0.48% 90
2018
Q2
$4.91M Buy
99,656
+38,626
+63% +$1.46M 0.77% 6
2018
Q1
$1.87M Buy
61,030
+26,212
+75% +$728K 0.31% 144
2017
Q4
$635K Buy
+34,818
New +$540K 0.11% 263
2016
Q1
Sell
-29,838
Closed -$943K 356
2015
Q4
$943K Buy
29,838
+4,608
+18% +$163K 0.12% 285
2015
Q3
$868K Sell
25,230
-13,524
-35% -$409K 0.14% 274
2015
Q2
$1.22M Buy
+38,754
New +$1.14M 0.14% 271

Other funds holding MRTX

EAM Investors's MRTX Position: Q1 2021 in Review

EAM Investors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2021, closing a stake of 11,552 shares — an estimated $2.54M sold.

EAM Investors first reported a position in MRTX in Q2 2015 and held it in 13 quarters. The position peaked at $4.91M in Q2 2018. 260 funds tracked by Wall St. Rank hold MRTX as of Q1 2021.

  • EAM Investors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • EAM Investors sold 11,552 Mirati Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2.54M.
  • EAM Investors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2015 and held it in 13 quarters.
  • EAM Investors's Mirati Therapeutics, Inc. Common Stock position peaked at $4.91M in Q2 2018.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2021.

Based on EAM Investors's 13F filing for Q1 2021, filed 11 May 2021.